Find trials
Search tips

Alterations of Pulmonary Vascular System in Patients Supported By Continuous Flow Left Ventricle Assist Device (LVAD)

Overview

About this study

The purpose of this study is to assess the impact of continuous-flow Left Ventricle Assist Device (LVAD) therapy and total artificial heart  (TAH) therapy on the alveolar-capillary interface and bronchial circulation of lungs in patients with heart failure (HF).

Participation eligibility

Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. There is no guarantee that every individual who qualifies and wants to participate in a trial will be enrolled. Contact the study team to discuss study eligibility and potential participation.

Inclusion Criteria:

  • >18 years of age
  • Females must be non-pregnant or not of child-bearing potential 
  • Receiving a CF LVAD (Heart Mate II® or Heart Ware®) indicated for long-term LVAD support

Participating Mayo Clinic locations

Study statuses change often. Please contact the study team for the most up-to-date information regarding possible participation.

Mayo Clinic Location Status

Rochester, Minn.

Mayo Clinic principal investigator

Bruce Johnson, Ph.D.

Closed for enrollment

More information

Publications

Publications are currently not available

More about research at Mayo Clinic

.
CLS-20307908

Mayo Clinic Footer